This study will compare the effectiveness of two different treatments for preventing infection from frostbite injuries. These two treatments are A) aloe vera and B) long-acting silver wound dressings. The investigators will also study the safety and effectiveness of Dalbavancin, an FDA approved antibiotic used for treating people who develop frostbite wound infections, as well as evaluate how frostbite damage to individuals' bodies may affect how fast their kidney clear drugs from their systems.

Start Date01 Mar 2024

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT05117398 / RecruitingPhase 3

Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus

The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic therapy for 14 days according to national guidelines at DAY 30 (Long follow up visit).
As the secondary objectives, the study aims to evaluate according to treatment group:
Cure rate at DAY 14 and DAY 90 (EOS);
Mortality rate within 90 days of follow-up;
Time to negativation of blood cultures;
Patient's quality of life;
Hospitalization length of stay;
Cost-utility analyses;
Occurrence of any adverse event (AE and SAE), until Day 90 (EOS).

Start Date23 Jun 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

[+3]

NCT03982030 / WithdrawnPhase 4IIT

An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy

The purpose of this research is to determine if a new antibiotic called dalbavancin will work to treat and cure certain infections while reducing the need for daily antibiotics by vein.

Start Date01 Apr 2023

Sponsor / Collaborator

Wake Forest School of Medicine

100 Clinical Results associated with Dalbavancin Hydrochloride

100 Translational Medicine associated with Dalbavancin Hydrochloride

100 Patents (Medical) associated with Dalbavancin Hydrochloride

695

Literatures (Medical) associated with Dalbavancin Hydrochloride

01 Mar 2024·Journal of global antimicrobial resistance

Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

Article

Author: Cattaneo, Agnese ; Gentile, Ivan ; De Rosa, Francesco Giuseppe ; Grossi, Paolo Antonio ; Comandini, Alessandro ; Morata Ruiz, Laura ; Ruggieri, Alessandro ; Moreno Núñez, Leonor ; Falcone, Marco ; Cascio, Antonio ; Salavert Lletí, Miguel ; Pasquau Liaño, Juan ; Ori, Alessandra ; Tascini, Carlo ; Loeches Yagüe, Maria

OBJECTIVES:

To retrospectively describe the patterns of use of dalbavancin for treating infections in diabetic patients in Italian and Spanish standard clinical practice.

METHODS:

DALBADIA [NCT04959799] was a multicentre, observational, retrospective cohort study, conducted in Italy and Spain. The study enrolled 97 adults with type 1 or 2 diabetes mellitus, treated with dalbavancin as per standard clinical practice for a Gram-positive bacterial infection or the Gram-positive component of a mixed infection.

RESULTS:

Dalbavancin was used to treat cellulitis (18/92 patients, 19.6%), followed by prosthetic joint infection (14 patients, 15.2%), endocarditis (13 patients, 14.1%), and primary bacteraemia (10 patients, 10.9%); 78/92 (84.8%) patients had Gram-positive infections only, and 14 (15.2%) had mixed infections. The most frequently isolated microorganisms were Staphylococcus aureus in 43 (55.8% of the patients with microbial isolation), 25.6% of which methicillin-resistant; Staphylococcus epidermidis in 13 (16.9%), 53.8% of which methicillin-resistant; Enterococcus faecalis in 11 (14.3%). The main reason for the dalbavancin choice was the intent to simplify the antibiotic regimen (81.5% of cases). A multidisciplinary team participated in the treatment choice process for 53 (57.6%) patients. Dalbavancin was given as first-line antibiotic in 34 (37.0%) patients and administered as one infusion in 32 (34.8%), and as two infusions in 39 (42.4%). In total, 57/62 (91.9%) eligible patients with available assessment were judged clinically cured or improved at the end of observation.

CONCLUSION:

In clinical practice, dalbavancin was used in diabetic patients to treat ABSSSIs and other difficult-to-treat infections with a favourable safety profile and a high rate of positive clinical responses.

01 Feb 2024·Infectious diseases now

Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis

Article

Author: Thill, Pauline ; Robineau, Olivier ; Joulie, Donatienne ; Patoz, Pierre ; Blondiaux, Nicolas ; Senneville, Eric ; Pradier, Maxime ; Hennart, Benjamin ; Lafondesmurs, Barthelemy ; Boucher, Anne

OBJECTIVES:

We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.

PATIENTS AND METHODS:

Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.

RESULTS:

Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.

CONCLUSIONS:

In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.

01 Feb 2024·Diagnostic microbiology and infectious disease

Case report: Prosthetic aortic valve endocarditis due to Staphylococcus epidermidis with acquired resistance in the walK gene

Author: Loeches, Belen ; Cepeda, Javier Gonzalez ; Sanchez, Ivan Bloise ; Perona, Fernando Lázaro ; Rico, Alicia ; Calvo, Juana Cacho

We report the case of a patient with infective endocarditis on a prosthetic aortic valve due to Staphylococcus epidermidis, not a candidate for prosthetic replacement surgery. After three months of supressive treatment with dalbavancin, fever reappears, with growth of S. epidermidis. Susceptibility testing showed new-onset resistance to dalbavancin, with a mutation in walK gene.

News (Medical) associated with Dalbavancin Hydrochloride

14 Oct 2022

·www.ema.europa.eu

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022

10 new medicines recommended for approval EMA’s human medicines committee ( CHMP ) recommended 10 medicines for approval at its October 2022 meeting. The CHMP recommended granting a marketing authorisation for Dengue Tetravalent Vaccine (Live, Attenuated) Takeda for the prevention of dengue virus serotypes 1, 2, 3 and 4 in people from four years of age. Dengue is a mosquito-borne tropical disease caused by the dengue virus, leading to mild flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage. The global estimated death rate is 20,000 to 25,000 per year, primarily in children. Dengue tetravalent vaccine prevents fever, severe disease and hospitalisation caused by any of the four serotypes of the dengue virus. This vaccine received an EMA recommendation under the EU Medicines for all (EU-M4All) programme, a mechanism that allows the CHMP to assess medicines that are intended for use in low- and middle-income countries outside of the European Union (EU). Simultaneously, the vaccine has also received a positive opinion for use in the EU, under the trade name Qdenga . See more information in the news announcement in the grid below. The committee adopted a positive opinion for a marketing authorisation under exceptional circumstances for the advanced therapy medicinal product (ATMP) Ebvallo * (tabelecleucel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. This ATMP is intended for adult and paediatric patients who experience a serious complication following solid organ transplantation or bone marrow transplantation. Ebvallo was supported through EMA's PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. See more information in the news announcement in the grid below. Eladynos (abaloparatide) received a positive opinion for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. The committee recommended granting a marketing authorisation under exceptional circumstances for Livmarli * (maralixibat chloride) intended for the treatment of cholestatic pruritus (itching) in adult and paediatric patients from two months of age with Alagille syndrome, an inherited condition in which bile builds up in the liver. The CHMP gave a positive opinion for Locametz (gozetotide), which is intended for the diagnosis of prostate cancer. The committee adopted a positive opinion for Pluvicto (lutetium ( 177 Lu) vipivotide tetraxetan) for the treatment of prostate cancer. Spevigo (spesolimab) received a positive opinion for a conditional marketing authorisation for the treatment of flares in adult patients with generalised pustular psoriasis, a skin disorder that consists of pus spots surrounded by areas of red skin. The committee adopted positive opinions for three generic medicines : Dimethyl fumarate Teva (dimethyl fumarate), indicated for the treatment of adult and paediatric patients aged 13 years and older with multiple sclerosis, a chronic disease affecting the central nervous system. Pemetrexed Baxter (pemetrexed) for the treatment of malignant pleural mesothelioma, a rare cancer of the lining around the lungs, and non-small cell lung cancer. Plerixafor Accord (plerixafor) for the treatment of adults and children with lymphoma and multiple myeloma, two types of white blood cells cancers. Recommendations on extensions of therapeutic indication for four medicines The committee recommended four extensions of indication for medicines that are already authorised in the EU: Brukinsa , Libtayo , Lyumjev and Xydalba . Withdrawals of initial applications The applications for marketing authorisation for biosimilar medicines Tuznue and Hervelous were withdrawn by the applicant during the re-examination of the negative opinions that the committee adopted at its May 2022 meeting. These medicines were intended for the treatment of certain forms of breast cancer and gastric (stomach) cancer. A question-and-answer document on the withdrawals is available in the grid below. COVID-19 update The committee recommended converting the conditional marketing authorisation of the COVID-19 vaccine Vaxzevria to a standard marketing authorisation . Agenda and minutes The agenda of the October 2022 CHMP meeting is published on EMA's website. Minutes of the September 2022 CHMP meeting will be published in the coming weeks. CHMP statistics Key figures from the October 2022 CHMP meeting are represented in the graphic below. * This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products ( COMP ) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity . Positive recommendations on new medicines Name of medicine Ebvallo International non-proprietary name (INN) tabelecleucel Marketing-authorisation applicant Atara Biotherapeutics Ireland Limited Therapeutic indication Treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease More information Ebvallo: Pending EC decision News announcement: First therapy to treat transplant patients with post-transplant lymphoproliferative disease Name of medicine Eladynos INN abaloparatide Marketing-authorisation applicant Radius Health Ireland Ltd Therapeutic indication Treatment of osteoporosis in postmenopausal women at increased risk of fracture More information Eladynos: Pending EC decision Name of medicine Livmarli INN maralixibat chloride Marketing-authorisation applicant Mirum Pharmaceuticals International B.V. Therapeutic indication Treatment of cholestatic pruritus in patients with Alagille syndrome More information Livmarli: Pending EC decision Name of medicine Locametz INN gozetotide Marketing-authorisation applicant Novartis Europharm Limited Therapeutic indication Diagnosis of prostate cancer More information Locametz: Pending EC decision Name of medicine Qdenga Common name dengue tetravalent vaccine (live, attenuated) Marketing-authorisation applicant Takeda GmbH Therapeutic indication Prevention of dengue disease More information Qdenga: Pending EC decision Name of medicine Pluvicto INN lutetium (177Lu) vipivotide tetraxetan Marketing-authorisation applicant Novartis Europharm Limited Therapeutic indication Treatment of prostate cancer More information Pluvicto: Pending EC decision Name of medicine Spevigo INN spesolimab Marketing-authorisation applicant Boehringer Ingelheim International GmbH Therapeutic indication Treatment of flares in adult patients with generalised pustular psoriasis More information Spevigo: Pending EC decision Positive recommendations on new generic medicines Name of medicine Dimethyl fumarate Teva INN dimethyl fumarate Marketing-authorisation holder TEVA GmbH Therapeutic indication Treatment of multiple sclerosis More information Dimethylfumarate Teva: Pending EC decision Name of medicine Pemetrexed Baxter INN pemetrexed Marketing-authorisation applicant Baxter Holding B.V. Therapeutic indication Treatment of malignant pleural mesothelioma and non-small cell lung cancer More information Pemetrexed Baxter: Pending EC decision Name of medicine Plerixafor Accord INN plerixafor Marketing-authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of lymphoma and multiple myeloma More information To be published shortly Positive recommendations on extensions of indications Name of medicine Brukinsa INN zanubrutinib Marketing-authorisation holder BeiGene Ireland Ltd More information Brukinsa: Pending EC decision Name of medicine Libtayo INN cemiplimab Marketing-authorisation holder Regeneron Ireland Designated Activity Company (DAC) More information Libtayo: Pending EC decision Name of medicine Lyumjev INN insulin lispro Marketing-authorisation holder Eli Lilly Nederland B.V. More information Lyumjev: Pending EC decision Name of medicine Xydalba INN dalbavancin Marketing-authorisation holder AbbVie Deutschland GmbH & Co. KG More information Xydalba: Pending EC decision Withdrawals of initial marketing authorisation applications Name of medicine Hervelous INN trastuzumab Marketing-authorisationapplicant Prestige Biopharma Belgium More information Hervelous: Withdrawn application Name of medicine Tuznue INN trastuzumab Marketing-authorisationapplicant Prestige Biopharma Belgium More information Tuznue: Withdrawn application Positive recommendations on medicines for use outside the European Union Name of medicine Dengue Tetravalent Vaccine (Live, Attenuated) Takeda Common name dengue tetravalent vaccine (live, attenuated) More information Dengue Tetravalent Vaccine (Live, Attenuated) Takeda News announcement: New vaccine to protect people in the EU and worldwide against dengue Other updates List item Overview of (invented) names reviewed in September 2022 by the Name Review Group (NRG) adopted at the CHMP meeting of 10-13 October 2022 (PDF/142.16 KB) (new) Adopted First published: 14/10/2022 EMA/825713/2022 List item Scientific advice and protocol assistance adopted during the CHMP meeting 10-13 October 2022 (PDF/242.62 KB) (new) Adopted First published: 14/10/2022 EMA/CHMP/SAWP/827118/2022

VaccineBiosimilar

06 Jul 2022

·www.biospace.com

Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies against Solid Tumors

LAUSANNE, Switzerland--(BUSINESS WIRE)-- Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, today announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well as contributions from Gnubiotics. This press release features multimedia. View the full release here: (Graphic: Business Wire) Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target especially in immunotherapy resistant patient cohorts. The sponsored project will advance GNU201 and GNU101, as potential first-in-class immunotherapeutics that steer immune responses to control growth in solid tumors expressing altered O-glycan profiles thus responding to a critical need in non-responding patients. The multi-year project which will include dose-finding and key translational studies, forms a core part of a broader preclinical development plan that will support an Investigational New Drug Application (IND). “This support from Innosuisse and continued close collaboration with Prof. Michael Scharl`s group at the University Hospital Zürich provide further validation of our GLAAD platform, which holds great therapeutic potential for anti-PD-1 resistant and other non-responsive patient cohorts” stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer. Gnubiotics presented compelling data recently at the 2022 American Society of Clinical Oncology (ASCO) annual meeting showing the effect of its glycopeptides platform in driving robust T-cell immune responses against anti-PD-1 resistant tumors in a colorectal cancer mouse model. Also announced recently, was a collaboration with the University of Pennsylvania to explore CAR-T therapy in combination with Gnubiotics’ glycopeptides to enhance CAR-T efficacy in solid tumors. About GLAAD Glycopeptides are the foundation of Gnubiotics’ GLAAD molecules. GLAAD relies on glycopeptides as providers of antigenicity and adjuvanticity to the immune system. Gnubiotics’ GLAAD candidates are made of a range of glycans uniquely bound to peptides and can act directly on immune cells and modulate the microbiome. Combined, these modes of action influence the immune system responses which opens new ways to address areas where the immune system plays a role, including oncology, inflammatory and infectious diseases. About Innosuisse Innosuisse is the Swiss Innovation Agency. Its role is to promote science-based innovation in the interest of the economy and society in Switzerland. Innosuisse especially promotes the partnership between academia and the market with innovation projectslaying the groundwork for successful Swiss start-ups as well as innovative products and services. View source version on businesswire.com: Contacts Yemi Adesokan, Ph.D. Chief Executive Officer Email: info@gnubiotics.com Source: Gnubiotics Sciences Smart Multimedia Gallery Photo (Graphic: Business Wire) Logo View this news release and multimedia online at:

CollaborateFirst in ClassImmunotherapyASCO

22 Jun 2022

·www.prnewswire.com

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market Insights

SEATTLE, June 22, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 10,263.5 million in 2022 and is expected to exhibit a CAGR of 9.0% over the forecast period (2022-2030). Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Key trends in market include widespread presence of acute bacterial skin and skin structure infections (ABSSSI); increasing approval of novel drugs for acute bacterial skin and skin structure infections (ABSSSI), and increasing collaborations, acquisitions, and partnerships among key players. These key trends are expected to aid in growth of the global acute bacterial skin and skin structure infections (ABSSSI) market. According to an article published in the PLOS One journal, a peer-reviewed open access scientific journal in July 2020, the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was found to be 64% (abscess and/or cellulitis), on the basis of data collected between October 2017 and March 2019. Moreover, rapid research and development in the field of acute bacterial skin and skin structure infections (ABSSSI) for development of novel treatment for the same is expected to fuel market growth over the forecast period. For instance, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be administered as a single- or two-dose regimen for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Furthermore, key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market are focusing on adoption of inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their market presence in the global market. For instance, in May 2020, Advanz Pharma, a U.K.-based pharmaceutical company, announced that it had completed the acquisition of Correvio Pharma Corp., a Canada-based specialty pharmaceutical company whose product portfolio includes licensed medicines such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Request Sample Copy of this Report @ Key Market Takeaways: Global acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising focus of market players on regulatory approvals for novel acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in July 2021, AbbVie Inc. ., a U.S. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered as an intravenous (IV) infusion for the treatment of pediatric patients with ABSSSI caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. Among infection type, community acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to rising drug launches by market players for treatment of community acquired acute bacterial skin and skin structure infections (ABSSSI). For instance, in February 2021, Paratek Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it is expanding commercial launch of its tetracycline-class oral antibiotic Nuzyra (omadacycline) into the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI). Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd. Request for Customization @ Detailed Segmentation: Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type: Oral & Parenteral Antibiotics Vancomycin Linezolid Clindamycin Ceftaroline Daptomycin Dalbavancin Tedizolid Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others) Topical Antibiotics Hydrogen Peroxide Fusidic Acid Mupirocin Retapamulin Povidone-Iodine Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type: Hospital Acquired ABSSSI Community Acquired ABSSSI Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration: Oral Parenteral Topical Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region: North America By Country: U.S. Canada Europe By Country: U.K. Germany Italy France Spain Russia Rest of Europe Asia Pacific By Country: China India Japan ASEAN Australia South Korea Rest of Asia Pacific Latin America By Country: Brazil Mexico Argentina Rest of Latin America Middle East & Africa By Country: GCC Countries Israel South Africa Rest of Middle East & Africa Buy this Complete Report Now @ Find related trending report below: North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market , by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: Follow Us: LinkedIn | Twitter Logo: SOURCE Coherent Market Insights

AcquisitionCollaborate

100 Deals associated with Dalbavancin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dalbavancin Hydrochloride	J01XA04	DB06219

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Skin and skin structure infections	US	AbbVie, Inc.	23 May 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	US	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	BG	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	CL	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	CO	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	GE	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	GR	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	GT	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	LV	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	MX	AbbVie, Inc.	31 Mar 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	PA	AbbVie, Inc.	31 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03372941 (CTgov)	Phase 4	Skin and skin structure infections \| Skin Diseases, Infectious	11	Dalbavancin (Alternative Treatment Strategy)	yaxgunbart(ocmnxcuifu) = xysqlhbzua qhrreabmla (vdqfafsigg, hitgqygfin - oqupaijkht) View more	-	09 Dec 2022
				vancomycin (Usual Care)	yaxgunbart(ocmnxcuifu) = fzmlcjxzzc qhrreabmla (vdqfafsigg, oefwyeadrh - ckspllelfg) View more
NCT02961764 (Pubmed)	Phase 4	Soft Tissue Infections	313	Long-Acting Intravenous Antibiotic (Usual care)	telzyydsva(smxkicaurk) = csnkibnnrx byqlmxfime (bczxuhygih ) View more	Positive	29 Mar 2021
				Long-Acting Intravenous Antibiotic (Clinical pathway)	telzyydsva(smxkicaurk) = hseunbfbfk byqlmxfime (bczxuhygih ) View more
NCT02940730 (CTgov)	Phase 4	Infectious peritonitis	10	Dalbavancin via Intravenous Administration (Dalbavancin Via IV)	prqdfjnaaa(umpnsotrmr) = kyrvrdhynp cpqbzvbnke (fnnsklgmje, gyxddotqwc - iqgilyclzh) View more	-	19 Mar 2021
				Dalbavancin via Intraperitoneal Administration (Dalbavancin Via IP)	prqdfjnaaa(umpnsotrmr) = adjufxyfra cpqbzvbnke (fnnsklgmje, capdklfarp - drkaolkxne) View more
NCT02961764 (CTgov)	Phase 4	Skin and skin structure infections	313	Usual Care (Usual Care)	rkysiptdzs(faktbegaok): Odds Ratio (OR) = 0.289 (95% CI, 0.156 - 0.532), P-Value = <0.001 View more	-	10 Apr 2020
				Dalbavancin (New Critical Pathway)
NCT03233438 (ENHANCE ABSSSI, Pubmed \| Infect Dis Ther)	Phase 4	Skin and skin structure infections	91	Dalbavancin	zoxojuqblp(ucdlxlvkzn) = 17% (n = 7) were found to have possible causal relation to dalbavancin in the post-period ggqfzhlvfu (eomlmwiloc ) View more	-	01 Mar 2020
				Dalbavancin (Usual care)
NCT02685033 (CTgov)	Phase 2	Osteomyelitis	80	Dalbavancin (Dalbavancin)	fohkrcxniw(deoeyqpejo) = aqsdihftsy bgjybcemoi (ybectoknxs, mukbbtwegc - gdaafsjbzd) View more	-	04 Jan 2019
				Comparator (Standard of Care)	fohkrcxniw(deoeyqpejo) = frosmrqzcz bgjybcemoi (ybectoknxs, dexjycvbls - hyiatmqwfd) View more
NCT02685033 (Pubmed) Manual	Phase 2	Osteomyelitis	80	Dalbavancin	glolwrdsvl(jhnieetxqk) = ixnghqikzb dxqszfztfm (jyeszlxkdz ) View more	Positive	10 Dec 2018
				SOC	glolwrdsvl(jhnieetxqk) = hxiobplrio dxqszfztfm (jyeszlxkdz )
NCT03091439 (CTgov)	Phase 2	Osteomyelitis	1	Dalbavancin (Dalbavancin)	cbbjybzbcn(jtgjvnrxyr) = ysxpjoxjwg jskqiunbjt (dpklsfhfxb, xazelkarjk - zvrtpseqac) View more	-	26 Sep 2018
				Standard of Care (Standard of Care)	uthmnqmrkc(dhcpxferif) = xrfvmuqmtx pyycjqdnmc (hwkdobeoyh, ksxwfbohde - zjxdsvfipv) View more
NCT03148756 (CTgov)	Phase 2	Endocarditis, Bacterial \| Bacteremia	2	Dalbavancin (Dalbavancin)	duolswfgwc(yztxmxgwrh) = rwbfldsuoy fqbgklqfct (qqellmnoxi, fjvbjwthps - gnvlyluqoi) View more	-	10 Sep 2018
				Standard of Care (Standard of Care)	sbmotspufx(kxsdeukomv) = ayqnhxfnoe xwqzbhsmwd (xcpjfkvqbp, tyefdrtomm - fqtvavbbfh) View more
NCT02127970 (CTgov)	Phase 3	Abscess \| Surgical Wound Infection \| Skin and skin structure infections ... View more	698	Dalbavancin-matching Placebo+Dalbavancin (Single-Dose Dalbavancin)	kxeltzfmnd(ncpjxmylxk) = udlyijnnbd jdsapvdeih (wbgszbkeet, eekkfinzqf - lfmobtjhsx) View more	-	14 Aug 2018
				Dalbavancin (Two-Dose Dalbavancin)	kxeltzfmnd(ncpjxmylxk) = flrnusgxna jdsapvdeih (wbgszbkeet, ufiqmyyzru - rytefyknnq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis